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A diet rich in fruits and vegetables, and a grape-derived compound, resveratrol, have been linked to a reduced
incidence of colon cancer. In vitro and in vivo, resveratrol suppresses Wnt signaling, a pathway constitutively
activated in over 85 % of colon cancers.
Thirty participants were placed on a low resveratrol diet and subsequently allocated to one of three groups
ingesting 1/3-to-1 lb (0.15–0.45 kg) of grapes per day for 2 weeks. Dietary information was collected via 24-h recall.
Colon biopsies for biomarker analysis were obtained pre- and post-grape and evaluated for the expression of Wnt
pathway target genes and for markers of proliferation by RT-PCR and immunohistochemistry.
Participants lost an average of 2 · 6 lb (1.2 kg, p = 0 · 0018) during the period of grape ingestion. The expression of
CyclinD1 (p < 0 · 01), AXIN2, CD133 (p = 0 · 02) and Ki67 (p = 0 · 002) were all reduced after grape ingestion.
Individuals over 50 years of age and those with high dietary arginine consumption had increased basal expression
of CyclinD1, AXIN2, cMYC and CD133 (p value range 0 · 04 to <0 · 001) that, following grape ingestion, were
reduced to levels seen in younger participants.
The reduction in Wnt signaling and mucosal proliferation seen following short-term ingestion of 1/3–1 lb (0.15–0.45 kg)
of grapes per day may reduce the risk of mutational events that can facilitate colon carcinogenesis. The potential
benefit is most marked for high-risk older individuals and individuals whose diet is high in arginine intake. Dietary grape
supplementation may play a role in colon cancer prevention for high-risk individuals.
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Studies suggest strongly that a diet rich in fruits and
vegetables leads to a lower risk of colorectal cancer
(CRC) [1, 2]. Grape seeds and other grape-based prod-
ucts have purported CRC prevention activity [3], are rich
in polyphenols and contain resveratrol, anthocyanins,
catechins, quercetin and numerous other compounds
with chemopreventive potential [4]. The most intensively
studied component in grapes is resveratrol which sup-
presses PI3-kinase, AKT and NF-kB signaling pathways [5]* Correspondence: Randall.holcombe@mssm.edu
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creativecommons.org/publicdomain/zero/1.0/and may affect tumor growth by a myriad of other mecha-
nisms as well [6, 7]. Systemic administration of resveratrol
has been shown to inhibit the growth of intestinal tumors
in several different rodent cancer models [8, 9]. For colon
cancer prevention, effects are seen over a wide variety of
dose ranges depending on individual studies. Tessotore
[10] demonstrated activity of very low dose resveratrol of
0.2 mg/kg/day in reducing aberrant crypt foci (ACF) in
the colon in an azoymethane-induced tumor model. In an-
other carcinogen-based model, utilizing 1,2-dimethylhy-
drazine, resveratrol at 8 mg/kg/day reduced both ACF and
colonic tumors [11] as did gavage of 60 mg/kg body
weight [12]. In genetic models utilizing the APCmin/+
mouse, which harbors a single allele mutation in apc
and therefore has intrinsically activated Wnt signaling,ss article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
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as low as 0.3 mg/mouse/day in reducing intestinal tumors.
In this study, expression of Wnt target gene cyclinD1 as
well as other markers of cell cycling was reduced.
Resveratrol, even at low concentrations, blocks Wnt
signaling in colon cancer cells in vitro [14]. This pathway
is activated in over 85 % of CRC making it an attractive
target for a colon cancer prevention agent. Resveratrol-
rich freeze-dried grape powder has been utilized in a
pilot study in normal human volunteers and was found
to down-regulate the expression of Wnt pathway target
genes CyclinD1 and AXIN2 in colonic mucosa [15].
However, low bioavailability of individual compounds
such as resveratrol often results in systemic concentra-
tions too low to be clinically active [16]. Therefore, it is
important in consideration of dietary approaches to can-
cer prevention to consider the aggregate activity of all of
the bioactive components in a particular foodstuff [17]
and not just single purified compounds.
This phase I study was undertaken to evaluate the po-
tential role of a grape-supplemented diet for CRC pre-
vention. The endpoints were biologic biomarkers of
proliferation and Wnt signaling in colonic mucosa. Dur-
ing the study, detailed dietary information was collected
and analyzed. This study is unique in that the effects of
the complete foodstuff, rather than a refined component
(ie grape seed extract) or individual substance (ie resver-
atrol) on biologically relevant cancer prevention end-
points is being investigated.
Materials and methods
Clinical trial design and conduct
30 healthy non-diabetic volunteers were enrolled over
a period of 9 months for this study (clinical trial
NCT00578396) which was approved by the University of
California, Irvine institutional review board (ethics com-
mittee). Written informed consent was obtained for all
participants. One potential subject was excluded from
the study because of an elevated blood sugar discovered
during eligibility testing that included a complete blood
count and chemistry profile. This individual was referred
for evaluation of occult diabetes. All participants had an
initial consultation with a dietitian and were placed onto
a low resveratrol diet (no grapes, wine, raisins, peanuts,
peanut butter or cranberries) for 4 weeks. The con-
trolled resveratrol diet was instituted as a base diet prior
to sample acquisition and continued during the phase of
grape ingestion. This was done to ensure minimal im-
pact of potential dietary changes during the interven-
tional component of the study. 24 h dietary recall
evaluations were performed 3 times during days 1–14,
and three more times during days 15–30, with data en-
tered into a dietary software program “Nutrition Data
System for Research (NDSR) Versions 2006–2008”produced by the University of Minnesota. During days
15–30, participants were assigned to one of three grape
consumption cohorts: 1/3 lb, 2/3 lb or 1 lb (0.15 kg,
0.30 kg, 0.45 kg) of grapes to be ingested each day.
These amounts were selected by the investigators be-
cause 1/3 lb of grapes is equivalent to one “serving” as
defined by the United States Department of Agriculture
(USDA). Each patient was given a voucher redeemable
at a local grocery store for red, seedless grapes and a
digital kitchen scale. Compliance with grape consump-
tion was ascertained at the time of the 24 h recall evalu-
ations and again at the end of subject participation.
Assignment into the cohorts was determined by a ran-
dom sequential enrollment algorithm. Limited flexible
sigmoidoscopies were performed on day 15 (“pre-grape”)
and on day 30 (“post-grape”). Two-to-four rectal muco-
sal biopsies were obtained for RNA and immunohisto-
chemical analysis. See Fig. 1 for a schematic of the
clinical trial design.
24 hour dietary recall
Nutrition data system for research (NDSR) is a dietary
analysis program designed for the collection and ana-
lyses of 24-h dietary recalls and the analysis of food re-
cords, menus, and recipes. Nutrient intake from both
food and supplemental sources are captured and quanti-
fied. Dietary interviews took place over the telephone
and/or in person and data was entered directly into
NDSR. Food portion estimation visual aids and a kitchen
scale were provided to respondents to assist in portion
size estimation.
Quantitative Real-time PCR (qRT-PCR)
RNA was extracted from one-to-two of the biopsies ob-
tained from each of the “pre-grape” and “post-grape” sig-
moidoscopies using standard methodologies. Rectal
mucosal biopsies were analyzed by quantitative real-time
PCR for the expression of genes associated with prolifera-
tion and Wnt signaling including: ornithine decarboxylase
(ODC1), nemo-like kinase (NLK), cJUN, cMYC, cyclinD1
(CCND1), lymphoid enhancing factor-1 (LEF1, TCF7L3),
axinII (AXIN2), forkhead box protein 3 (FOXO3) and
CD133 (Prominin1, PROM1). Primer pairs were obtained
from Qiagen (Valencia, CA) with cycling parameters as
defined by the manufacturer. Wnt target gene mRNA
levels were all normalized to the housekeeping gene ribo-
somal RNA (rRNA). The relative RNA expression was cal-
culated by the comparative threshold cycle method. All
experiments were repeated in triplicate.
Immunohistochemical analysis
One-to-two of the biopsies obtained from each of the
“pre-grape” and “post-grape” sigmoidoscopies were im-

















Fig. 1 Schematic of the clinical trial design. The controlled reservatrol diet was maintained throughout the 4 week period. Grape ingestion
occurred during the final 2 weeks
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onto slides for Ki67 immunohistochemistry (IHC). The
percentage of cells expressing Ki67 in the lower 1/3 of
colonic crypts was determined by fluorescence confocal
microscopy. A minimum of 50 crypts were evaluated for





Age 43 · 28 ± 2 · 28 46 · 00 ± 3 · 02
Initial weight (lb) 172 · 1 ± 6 · 55 175 · 3 ± 16 · 30















BMI Body Mass Index
*1-way Anova with Newman-Keuls post testStatistical analysis
Patient characteristics were compared with 1-way
ANOVA with a Newman-Keuls post-test. Dietary changes
seen with grape supplementation, pre- and post-grape
gene expression by qRT-PCR and Ki67 expression scored





43 · 45 ± 4 · 79 40 · 10 ± 3 · 98 NS
171 · 4 ± 8 · 22 169 · 2 ± 7 · 67 NS













Holcombe et al. Nutrition Journal  (2015) 14:62 Page 4 of 8signed-rank test. Linear regression analysis was utilized to
generate r2 and p values for the comparison of AXIN2
and CCND1 expression. Comparison of expression levels
stratified for age or for dietary arginine intake was under-
taken with an unpaired t-test. Statistical significance was
defined at a level of p < 0 · 05.
Results
Clinical trial and dietary analysis results
There were no statistically significant differences be-
tween the any of the three cohorts of grape consumption
for age, initial weight or body mass index (BMI; Table 1).
Results related to dietary changes were not statistically
different across the three cohorts and therefore dataChange in individual weights





















Change in mean weight













Fig. 2 Change in individual (a) and mean (b) weights for the 30 participants fr
Grape ingestion significantly reduced expression as measured by qRT-PCR of C
AXIN2 (d). However, CyclinD1 and AXIN2 levels in colonic mucosa were strong
ingestion (i). Ki67 expression was also reduced following grape ingestion (f). Th
in the lower 1/3 of colonic crypts (g; representative photomicrograph—green
*** p < 0 · 005were combined for presentation in this report. More fe-
males participated in the study. The race/ethnicity of the
subjects is depicted in Table 1. No toxicities were re-
ported for any of the 30 participants in the clinical trial.
Toxicities were monitored by detailed interviews by re-
search personnel. Compliance with the assigned grape
consumption daily ingestion was 100 % for the two week
period being monitored. All participants said they were
compliant with the dietary restrictions to limit resveratrol-
containing foods for the entire 4 week study period.
During the two weeks of grape consumption, partici-
pants lost an average of 2 · 6 lbs (1 · 2 Kg; p = 0 · 0018;
Fig. 2) despite significant increases in total carbohydrates,







om pre-grape ingestion timepoint to the post-grape ingestion timepoint.
yclinD1 (c) and CD133 (e) with a non-statistically significant reduction in
ly correlated with each other both pre-grape ingestion (h) and post-grape
is was measured by calculating the percentage of positively staining cells
represents positive immunofluorescence). *p < 0 · 05; ** p < 0 · 01;
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reported that they often felt “full”, particularly those con-
suming 1 lb (0.45 kg) of grapes per day, and subjectively
reported that they snacked less because of this. Interest-
ingly, there was a significant reduction in the percentage
of calories from fat (35 · 32 to 30 · 77 %) while ingesting
grapes (p = 0 · 011; Table 2). Other significant changes in-
cluded an increase in copper, potassium and vitamin B6
and a decrease in Biochanin A ingestion.
Changes in markers of proliferation and Wnt signaling
Results related to changes in proliferation and Wnt sig-
naling markers were not statistically different across the
three cohorts. In general the magnitude of the changes
was slightly greater in the 1 lb/day (0.45 kg) cohort than
the 2/3 lb/day (0.30 kg) and 1/3 lb/day (0.15 kg) cohorts
but the direction of the changes were consistent
throughout all 3 groups. Each cohort contained only ten
participants and therefore data for all participants were
combined for presentation in this report. RT-PCR analysis
revealed a significant reduction in the expression of
CyclinD1, a proliferation marker and target gene for Wnt
signaling, following grape ingestion (Fig. 2; p < 0.01). A
trend toward reduction in another Wnt target gene,
AXIN2 was seen and the pre- and post-grape expression
levels of CyclinD1 correlated significantly with the corre-
sponding levels of AXIN2 (Fig. 1). The expression of
CD133, a colonic stem cell marker was also significantly
reduced (p = 0 · 02). The expression of Ki67 protein, as
measured by the percentage of expressing cells in the
lower 1/3 of colonic crypts, was significantly reducedTable 2 Dietary changes observed with grape supplementation
Parameter Pre-grape baseline At conclusion
Weight (lbs) 172 · 1 ± 6 · 55 170 · 7 ± 7 · 65
KCALS 1960 ± 131 · 2 1984 ± 125 · 1
Carbohydrate (gm) 233 · 4 ± 15 · 8 271 · 3 ± 18 · 2
Calories from carbohydrate (%) 46 · 99 ± 1 · 58 51 · 87 ± 1 · 53
Total sugars (gm) 92 · 49 ± 7 · 86 131 · 9 ± 9 · 44
Calories from fat (%) 35 · 32 ± 1 · 44 30 · 77 ± 1 · 20
Copper (mg) 1 · 32 ± 0 · 13 1 · 53 ± 0 · 11
Potassium (mg) 2566 ± 189 3004 ± 203
Vitamin B6 (mg) 1 · 957 ± 0 · 16 2 · 254 ± 0 · 21
Biochanin A (mg) 0 · 133 ± 0 · 07 0 · 013 ± 0 · 01
Folate (mcg) 486 · 2 ± 41 · 8 433 · 0 ± 41 · 1
Cholesterol (mg) 289 · 3 ± 34 · 93 262 · 0 ± 28 · 0
Genistein (mg) 2 · 53 ± 1 · 11 0 · 61 ± 0 · 20
Lycopene (mcg) 4798 ± 726 4064 ± 702
Arginine (gm) 4 · 503 ± 0 · 41 4 · 276 ± 0 · 34
Dietary components listed as amount ingested per day
*Wilcoxon matched pairs signed rank testfollowing grape ingestion (p = 0 · 002; Fig. 2). While the
expression of several of the other genes tested had consist-
ent trends, none, including cMYC, reached statistical
significance.
Effect of age and grape diet on markers of proliferation
and Wnt signaling
Data across all cohorts was stratified by age of participant.
Twenty one participants were aged 18–49 and 9 were aged
50 and over. Several markers of Wnt signaling and prolif-
eration were very significantly increased in older partici-
pants including CyclinD1 (p = 0 · 022), AXIN2 (p = 0 · 040)
and cMYC (p = 0 · 006). The stem cell marker CD133 also
had significantly increased expression in older individuals
(p < 0 · 001; Fig. 3). As can be seen in Fig. 2, virtually all of
the effect of grape ingestion was on the older participants,
with no change in expression seen for any of these four
markers in the 18–49 year old group and significant re-
ductions seen in the 50 and older group. In most cases,
the effect of grape ingestion was to reduce the levels of ex-
pression of these markers to a level seen basally in the
younger participants (difference between “pre-younger”
and “post-older” not significant in all cases).
Effect of arginine intake and grape diet on markers of
proliferation and Wnt signaling
Participants were also stratified according to baseline ar-
ginine intake. The mean daily arginine intake was 4 ·
5gm/day. Twenty one participants had arginine ingestion
below the mean and nine participants had arginine in-
gestion above the mean. Expression of CyclinD1,of grape intervention Direction of change Significance (p)*
↓ 0 · 0018
↔ NS
↑ 0 · 0048
↑ 0 · 0089
↑ 0 · 0001
↓ 0 · 011
↑ 0 · 0035
↑ 0 · 0014
↑ 0 · 0193


























































































































































Fig. 3 Differences in expression of CyclinD1 (a), AXIN2 (b), cMYC (c) and CD133 (d) in participants below age 50 and 50 years old and above.
Prior to grape ingestion, older individuals had significantly higher levels of CyclinD1, AXIN2, cMYC and CD133 than individuals aged 18–49.
Grape ingestion in participants aged 50 and above led to a reduction in the expression CyclinD1 (p < 0 · 01), AXIN2, cMYC and CD133. Levels of
CyclinD1 and AXIN2 in participants aged 50 and above were reduced to levels seen prior to grape ingestion in 18–49 year olds. While reduced
after grape ingestion, the level of expression of cMYC and CD133 in participants aged 50 and above remained significantly elevated when
compared to the pre-grape ingestion levels of 18–49 year olds. *p < 0 · 05; **p < 0 · 01; ***p < 0 · 001
Holcombe et al. Nutrition Journal  (2015) 14:62 Page 6 of 8AXIN2, cMYC and CD133 were all significantly higher
in patients with high baseline arginine intake compared
to those with below average arginine intake (p values
ranging from 0 · 04 to 0 · 002; Fig. 4). Grape ingestion re-
sulted in a significant reduction in CyclinD1expression in
volunteers with high baseline dietary arginine consump-
tion (P < 0 · 0039), achieving expression levels below the
baseline CyclinD1 levels for patients in the low arginine
group. Reductions following grape ingestion were also
seen with cMYC, Axin2 and CD133 but these were not
statistically significant.
Discussion
Participants were able to tolerate up to a pound of grapes
per day for 2 weeks with full compliance and without any
adverse consequences. No patients with diabetes were en-
rolled on the trial based on a recommendation from theInstitutional Review Board (Ethics Committee) because of
the high sugar content of grapes. While on study, partici-
pants ingested less fat and lost, on average, 1 · 2 kg of
weight. While weight loss with grapes has been reported
previously in the popular press [18], to our knowledge this
is the first confirmation of this effect under controlled
clinical trial conditions.
The effects of a grape supplemented diet on Wnt sig-
naling and markers of proliferation were consistent with
prior in vitro [14] studies using resveratrol and an
in vivo [15] study using resveratrol supplements and
freeze-dried grape powder. Inhibition of Wnt signaling
and reduced colonic mucosal proliferation suggests po-
tential cancer preventative effects of a grape-containing
diet. Whether these effects are due to resveratrol alone
or other constituents of grapes, or a combination of con-
stituents, remains to be defined. This study was of short
C D
EBA
Fig. 4 Differences in expression of CyclinD1 (a), AXIN2 (b), cMYC (c) and CD133 (d) in participants with high baseline arginine consumption and
those with low baseline arginine consumption. Individuals with high arginine intake had significantly higher expression of each of these markers.
In those with high arginine intake, grape ingestion led to a statistically significant reduction in CyclinD1 expression to levels seen in those with
low arginine intake. Grape intervention did not significantly change the expression of CyclinD1 in participants with low initial arginine intake.
*P < 0 · 05; **p < 0 · 01; ***p < 0 · 005
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appearance of aberrant crypt foci or pre-cancerous co-
lonic adenomas. The significant changes noted after a
short period of exposure suggests that intermittent con-
sumption of grapes may be sufficient and this should be
considered in the design of future dietary-based cancer
prevention trials.
As the human colon ages, the inflammatory process
leading to mucosal injury and the regenerative capacity
of the epithelium are affected [19]. Telomere shortening,
methylation of mucosal healing-associated genes, and al-
terations of growth factor signaling occur and have been
postulated to affect the regenerative capacity of the epi-
thelium. In rats, an increase in the proliferation rate of
colonic mucosa is seen in conjunction with senescence
[20]. Diet restriction increases intestinal apoptosis in
aging rats, perhaps providing protection from an age-
related accumulation of DNA alterations [21]. Resvera-
trol has been shown to improve survival of mice on a
high calorie diet [22], possibly through its effects on
suirtuin-1 (SIRT1) activation [23]. Indeed, small mol-
ecule SIRT1 activators have been proposed for the treat-
ment of age-related disorders [24]. In our study, colonic
proliferation was significantly higher in older partici-
pants compared to younger participants. The effects of
grape ingestion were most dramatically seen in the older
population, with a reduction of both Wnt target genes
and markers of mucosal proliferation.
High levels of dietary arginine and the polyamine syn-
thesis pathway have been linked to colon carcinogenesis
in several types of animal models [25, 26]. This has also
been implicated in human colon carcinogenesis [27] anda randomized trial has demonstrated that an inhibitor of
polyamine synthesis, DFMO, reduces the incidence of
colon adenomas with high malignant potential [28]. Or-
nithine decarboxylase (ODC) catalyzes the rate-limiting
step in the biosynthesis of polyamines and is inhibited
by resveratrol, suggesting that one of the molecular
mechanisms through which resveratrol may be operating
is polyamine pathway inhibition [29]. In our study, diet-
ary arginine consumption was ascertained through the
diet survey instrument. When stratified for arginine con-
sumption, the effect on colonic mucosal proliferation
was most marked in participants who had higher levels
of arginine ingestion. Based on the ongoing dietary mon-
itoring and post-grape intervention data, this effect ap-
pears to have been due to the grape consumption and
not due to a reduction in arginine consumption over the
course of the study.
This study has significant implications for colon cancer
prevention. The reduction in Wnt signaling and mucosal
proliferation seen following relatively short-term ingestion
of 1/3–1 lb of grapes should reduce the risk for the devel-
opment of mutational events that can ultimately result in
colon carcinogenesis. The potential benefit is most
marked for older individuals and individuals whose diet is
high in arginine intake. Both of these groups have an in-
creased incidence of colon cancer [27, 30]. Subsequent
studies should focus on other high-risk populations such
as patients with a history of colonic adenomas (polyps)
and individuals with an inherited genetic predisposition
for colon cancer. Finally, patients with inflammatory
bowel disease may benefit from the anti-proliferative
effects of a grape-supplemented diet.
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